UBS Group Increases Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,099.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective increased by equities researchers at UBS Group from $1,090.00 to $1,099.00 in a report released on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. UBS Group’s price target would suggest a potential upside of 22.93% from the company’s current price.

A number of other equities analysts also recently issued reports on REGN. Sanford C. Bernstein started coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 target price for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Bank of America upped their price target on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research note on Friday, April 12th. Morgan Stanley lifted their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a report on Wednesday, March 13th. Finally, Barclays upped their price target on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a report on Tuesday, January 23rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $976.41.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $893.99 on Wednesday. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10. The company has a market cap of $98.12 billion, a P/E ratio of 25.73, a PEG ratio of 2.58 and a beta of 0.11. The firm’s 50 day moving average price is $954.14 and its 200 day moving average price is $890.55. Regeneron Pharmaceuticals has a fifty-two week low of $684.80 and a fifty-two week high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. The firm had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company’s revenue was up .6% on a year-over-year basis. During the same period last year, the firm posted $10.96 EPS. On average, research analysts forecast that Regeneron Pharmaceuticals will post 38.58 earnings per share for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In other news, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the completion of the sale, the executive vice president now directly owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the transaction, the executive vice president now owns 13,789 shares of the company’s stock, valued at $12,888,716.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Andrew J. Murphy sold 5,783 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the sale, the executive vice president now owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The disclosure for this sale can be found here. Insiders sold 13,729 shares of company stock worth $13,124,641 in the last 90 days. Corporate insiders own 8.83% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors have recently made changes to their positions in REGN. FMR LLC raised its stake in Regeneron Pharmaceuticals by 7.3% during the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock valued at $8,098,661,000 after purchasing an additional 669,517 shares during the last quarter. Vanguard Group Inc. increased its position in Regeneron Pharmaceuticals by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 8,838,285 shares of the biopharmaceutical company’s stock valued at $7,762,577,000 after acquiring an additional 39,780 shares in the last quarter. Capital World Investors raised its position in Regeneron Pharmaceuticals by 0.5% in the 4th quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock worth $4,506,071,000 after purchasing an additional 23,146 shares during the last quarter. Putnam Investments LLC lifted its stake in shares of Regeneron Pharmaceuticals by 2.1% during the fourth quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock valued at $1,063,377,000 after acquiring an additional 24,329 shares during the period. Finally, Northern Trust Corp grew its position in shares of Regeneron Pharmaceuticals by 3.3% during the 3rd quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company’s stock worth $878,271,000 after buying an additional 34,326 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.